Oncosure, a cancer diagnostics firm, has debuted its new Rapid Cancer Screening Test, designed to make early detection available to everyone.
The Oncosure test can screen for all types of cancer using a single blood draw at its earliest stages, including stage 1.
The advanced test provides precise, definitive results within hours, equipping the patient and healthcare provider with essential information to take prompt action.
In addition to its role in early detection, the Oncosure test will help in monitoring ongoing cancer treatments, helping evaluate their effectiveness.
Additionally, the non-invasive test provides key information for leading further imaging tests with detailed OncoSone count.
The technology is said to be both simple and comfortable for patients, making the testing experience smoother for patients, healthcare providers, and lab technicians.
For those in remission, it provides reassurance by identifying signs of recurrence early, when treatment options are most effective.
The test detects oncosomes, microscopic vesicles released by cancer cells, across all types of cancer. Utilising advanced fluorescent microscopy, it delivers precise and actionable results.
In addition, Oncosure said the Rapid Cancer Screening Test will help people if they are at high risk, experiencing symptoms, undergoing treatment, in remission, or assessing health status.
Oncosure vice president Jason Andrews said: “One blood draw, all cancers—this is the future of cancer screening.
“Cancer doesn’t wait for symptoms, and neither should you. Our test empowers everyone to screen for any type of cancer with a single, non-invasive test.”
Furthermore, the technology ensures highly accurate results with a sensitivity of 97.05%, specificity of 90.21%, and overall accuracy of 93.51%.
The precision lowers the likelihood of false positives or negatives, enhancing the reliability of the test results, Oncosure said.
In addition, the tests are priced 61% lower than existing options, making them more affordable and accessible than existing cancer screening options.
